SCHEMBL1924700

SCHEMBL1924700

CC(=O)c1sccc1NC(=O)Cn1cc(-c2ccccc2)c(=O)c2ccc(C)cc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK8 P45983 1/20 0.46
▸ MAPK10 P53779 1/20 0.46
▸ POLB P06746 5/20 0.46
▸ HTT P42858 3/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ LMNA P02545 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ MAPT P10636 3/20 0.43
▸ RXFP1 Q9HBX9 6/20 0.41
▸ TP53 P04637 2/20 0.41
▸ USP10 Q14694 2/20 0.41
▸ MEN1 O00255 4/20 0.40
▸ KMT2A Q03164 4/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ STAT3 P40763 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1924395 0.83 RAB9A (0.47) POLBHTTSMN1; SMN2LMNARAB9A
SCHEMBL1923602 0.81 CPT2 (0.55) HTTSMN1; SMN2LMNAMAPTRXFP1
SCHEMBL1923646 0.80 USP10 (0.46) POLBHTTSMN1; SMN2LMNARAB9A
SCHEMBL1923329 0.80 MARK4 (0.53) HTTSMN1; SMN2LMNAMAPTRXFP1
SCHEMBL1923448 0.79 USP10 (0.45) POLBHTTSMN1; SMN2LMNARAB9A
SCHEMBL1923590 0.79 USP10 (0.45) POLBHTTSMN1; SMN2LMNAMAPT
SCHEMBL1923474 0.79 KMT2A (0.47) POLBHTTSMN1; SMN2LMNARAB9A
SCHEMBL1923426 0.79 KDM4E (0.53) POLBSMN1; SMN2LMNAMAPTRXFP1
SCHEMBL1923521 0.79 CPT2 (0.50) HTTSMN1; SMN2LMNAMAPTRXFP1
SCHEMBL1923524 0.78 MAPT (0.55) POLBHTTSMN1; SMN2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2064185-B1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INT (ES) 2011-06-08 — — EP claimed
US-20100168099-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL, S.A. (ES) 2010-07-01 — — US claimed
CN-101522630-A 1H-quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions FERRER INT (ES) 2009-09-02 — — CN claimed
EP-2064185-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS Ferrer Internacional, S.A. (ES) 2009-06-03 — — EP claimed
WO-2008017710-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL S.A. (ES) 2008-02-14 — — WO claimed
EP-1886996-A1 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions FERRER INTERNACIONAL, S.A. (ES) 2008-02-13 — — EP claimed
EP-2064185-B1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INT (ES) 2011-06-08 — — EP disclosed
US-20100168099-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL, S.A. (ES) 2010-07-01 — — US disclosed
CN-101522630-A 1H-quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions FERRER INT (ES) 2009-09-02 — — CN disclosed
EP-2064185-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS Ferrer Internacional, S.A. (ES) 2009-06-03 — — EP disclosed
WO-2008017710-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL S.A. (ES) 2008-02-14 — — WO disclosed
EP-1886996-A1 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions FERRER INTERNACIONAL, S.A. (ES) 2008-02-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168099-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS GABRA1, GABRA4, GABRA2 MAPK8 4280/4885MAPK10 4272/4885POLB 3884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback